[Dyslipidemia in renal failure].
Fujioka
Takayuki
T
Second Department of Internal Medicine, Nihon University School of Medicine.
Ueno
Takahiro
T
Matsumoto
Taro
T
Watanabe
Hideyuki
H
D001161:Arteriosclerosis / Q000209:etiology; D002561:Cerebrovascular Disorders / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000209:etiology; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications*; D008079:Lipoproteins, VLDL / Q000097:blood; D009531:Niceritrol / Q000627:therapeutic use; D016491:Peripheral Vascular Diseases / Q000209:etiology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D015118:Eicosapentaenoic Acid; D009531:Niceritrol; D002994:Clofibrate